Skip to main content

News

The BPL Global Medical Publications Team expects a record year in 2022

23 June 2022

The Bio Products Laboratory (BPL) Global Medical Publications team expects a record year in 2022, with more scientific abstracts, posters, and manuscripts submitted or presented than in any year in the company’s history.

Read full article

BPL Featured in Manufacturing Today

20 June 2022

Bio Products Laboratory (BPL), a leading manufacturer in plasma-derived protein therapies, is pleased to share that we have been featured in the May Edition of Manufacturing Today.

Read full article

BPL Celebrates World Blood Donor Day

14 June 2022

Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, today celebrates World Blood Donor Day. The annual event serves to raise awareness of the importance of donating blood and the need for safe blood and blood products. The day is also an opportunity to thank all blood donors across the world.

Read full article

BPL expands options for patients in the Dominican Republic with marketing authorization for Coagadex®

01 June 2022

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today the issuance of a marketing authorization for Coagadex® in the Dominican Republic.

Read full article

BPL receives orphan drug marketing authorization for Coagadex® in Mexico

04 May 2022

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today it has received orphan drug marketing authorization for Coagadex® in Mexico.

Read full article

BPL Plasma opens its 29th donor centre

22 April 2022

Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, are pleased to announce that on 22 April, BPL Plasma opened its 29th plasma donation centre.

Read full article

BPL Celebrates World Hemophilia Day 2022

17 April 2022

Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, joins the global bleeding disorders community in recognition of World Hemophilia Day (WHD). Observed annually on 17 April, WHD honours Frank Schnabel’s birthday, a person who suffered from severe hemophilia, and subsequently established the World Federation of Hemophilia (WFH).

Read full article

BPL Marks Bleeding Disorders Awareness Month 2022

31 March 2022

Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, today marks the end of Bleeding Disorders Awareness Month1. Recognised every March, this month aims to help raise awareness of inheritable blood and bleeding disorders and the 300 million people affected by them worldwide.

Read full article

BPL granted a new patent in the US

30 March 2022

The United States Patent and Trademark Office granted a new patent (US Patent number: 11,149,079) to BPL for its ‘E+I’ process, granted in the US.

Read full article